Skip to main content
Top
Published in: BMC Nephrology 1/2021

Open Access 01-12-2021 | Acute Kidney Injury | Case report

Different renal manifestations associated with very early onset pediatric inflammatory bowel disease: case report and review of literature

Authors: A. Angeletti, S. Arrigo, A. Madeo, M. Molteni, E. Vietti, L. Arcuri, M. C. Coccia, P. Gandullia, G. M. Ghiggeri

Published in: BMC Nephrology | Issue 1/2021

Login to get access

Abstract

Background

Inflammatory bowel diseases are characterized by chronic inflammation of the gastrointestinal tract. In particular, Crohn disease and ulcerative colitis represent the two most common types of clinical manifestations. Extraintestinal manifestations of inflammatory bowel diseases represent a common complications, probably reflecting the systemic inflammation. Renal involvement is reported in 4–23% of cases. However, available data are limited to few case series and retrospective analysis, therefore the real impact of renal involvement is not well defined.

Case presentation

We report the case of a 10-years old male affected by very early onset unclassified-Inflammatory bowel diseases since he was 1-year old, presenting with a flare of inflammatory bowel diseases associated with acute kidney injury due to granulomatous interstitial nephritis. Of interest, at 7-year-old, he was treated for IgA nephropathy.
To our knowledge, no previous reports have described a relapse of renal manifestation in inflammatory bowel diseases, characterized by two different clinical and histological phenotypes.

Conclusions

The link between the onset of kidney injuries with flares of intestinal inflammation suggest that nephritis maybe considered an extra-intestinal manifestation correlated with active inflammatory bowel disease. However, if granulomatous interstitial nephritis represents a cell-mediated hypersensitivity reaction than a true extraintestinal manifestation of inflammatory bowel diseases is still not clarified. We suggest as these renal manifestations here described may be interpreted as extraintestinal disorder and also considered as systemic signal of under treatment of the intestinal disease.
Literature
1.
go back to reference Carvalho RS, Abadom V, Dilworth HP, Thompson R, Oliva-Hemker M, Cuffari C. Indeterminate colitis: a significant subgroup of pediatric IBD. Inflamm Bowel Dis. 2006;12(4):258–62.CrossRef Carvalho RS, Abadom V, Dilworth HP, Thompson R, Oliva-Hemker M, Cuffari C. Indeterminate colitis: a significant subgroup of pediatric IBD. Inflamm Bowel Dis. 2006;12(4):258–62.CrossRef
2.
go back to reference Uhlig HH, Charbit-Henrion F, Kotlarz D, Shouval DS, Schwerd T, Strisciuglio C, et al. Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel disease: a position paper from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2021;72(3):456–73.PubMed Uhlig HH, Charbit-Henrion F, Kotlarz D, Shouval DS, Schwerd T, Strisciuglio C, et al. Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel disease: a position paper from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2021;72(3):456–73.PubMed
3.
go back to reference Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390–407.CrossRef Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390–407.CrossRef
4.
go back to reference Giuffrida P, Di Sabatino A. Targeting T cells in inflammatory bowel disease. Pharmacol Res. 2020;159:105040.CrossRef Giuffrida P, Di Sabatino A. Targeting T cells in inflammatory bowel disease. Pharmacol Res. 2020;159:105040.CrossRef
5.
go back to reference Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96(4):1116–22.CrossRef Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96(4):1116–22.CrossRef
6.
go back to reference Ambruzs JM, Larsen CP. Renal manifestations of inflammatory bowel disease. Rheum Dis Clin N Am. 2018;44(4):699–714.CrossRef Ambruzs JM, Larsen CP. Renal manifestations of inflammatory bowel disease. Rheum Dis Clin N Am. 2018;44(4):699–714.CrossRef
7.
go back to reference Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(4):1034–45.CrossRef Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(4):1034–45.CrossRef
8.
go back to reference Bastuji-Garin S, Ochonisky S, Bouche P, Gherardi RK, Duguet C, Djerradine Z, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002;119(5):1020–6.CrossRef Bastuji-Garin S, Ochonisky S, Bouche P, Gherardi RK, Duguet C, Djerradine Z, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002;119(5):1020–6.CrossRef
9.
go back to reference Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–45.CrossRef Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–45.CrossRef
10.
go back to reference Working Group of the International Ig ANN, the Renal Pathology S, Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–56.CrossRef Working Group of the International Ig ANN, the Renal Pathology S, Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–56.CrossRef
11.
go back to reference Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353(9156):883–7.CrossRef Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353(9156):883–7.CrossRef
12.
go back to reference Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol. 2014;9(2):265–70.CrossRef Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol. 2014;9(2):265–70.CrossRef
13.
go back to reference Jang HM, Baek HS, Kim JE, Kim JY, Lee YH, Cho HY, et al. Renal involvement in children and adolescents with inflammatory bowel disease. Korean J Pediatr. 2018;61(10):327–31.CrossRef Jang HM, Baek HS, Kim JE, Kim JY, Lee YH, Cho HY, et al. Renal involvement in children and adolescents with inflammatory bowel disease. Korean J Pediatr. 2018;61(10):327–31.CrossRef
14.
go back to reference Archimandritis AJ, Weetch MS. Kidney granuloma in Crohn's disease. BMJ. 1993;307(6903):540–1.CrossRef Archimandritis AJ, Weetch MS. Kidney granuloma in Crohn's disease. BMJ. 1993;307(6903):540–1.CrossRef
15.
go back to reference Izzedine H, Simon J, Piette AM, Lucsko M, Baumelou A, Charitanski D, et al. Primary chronic interstitial nephritis in Crohn’s disease. Gastroenterology. 2002;123(5):1436–40.CrossRef Izzedine H, Simon J, Piette AM, Lucsko M, Baumelou A, Charitanski D, et al. Primary chronic interstitial nephritis in Crohn’s disease. Gastroenterology. 2002;123(5):1436–40.CrossRef
16.
go back to reference Hubert D, Beaufils M, Meyrier A. Immunoglobulin a glomerular nephropathy associated with inflammatory colitis. Apropos of 2 cases. Presse Med. 1984;13(17):1083–5.PubMed Hubert D, Beaufils M, Meyrier A. Immunoglobulin a glomerular nephropathy associated with inflammatory colitis. Apropos of 2 cases. Presse Med. 1984;13(17):1083–5.PubMed
17.
go back to reference Ridder RM, Kreth HW, Kiss E, Grone HJ, Gordjani N. Membranous nephropathy associated with familial chronic ulcerative colitis in a 12-year-old girl. Pediatr Nephrol. 2005;20(9):1349–51.CrossRef Ridder RM, Kreth HW, Kiss E, Grone HJ, Gordjani N. Membranous nephropathy associated with familial chronic ulcerative colitis in a 12-year-old girl. Pediatr Nephrol. 2005;20(9):1349–51.CrossRef
18.
go back to reference Pohjonen J, Nurmi R, Metso M, Oksanen P, Huhtala H, Porsti I, et al. Inflammatory bowel disease in patients undergoing renal biopsies. Clin Kidney J. 2019;12(5):645–51.CrossRef Pohjonen J, Nurmi R, Metso M, Oksanen P, Huhtala H, Porsti I, et al. Inflammatory bowel disease in patients undergoing renal biopsies. Clin Kidney J. 2019;12(5):645–51.CrossRef
19.
go back to reference Ota M, Iwai H, Imai K, Kamiya M, Yoshihashi-Nakazato Y, Miyasaka N, et al. Acute Tubulointerstitial nephritis associated with infliximab in a patient with Crohn’s disease. Intern Med. 2016;55(10):1367–70.CrossRef Ota M, Iwai H, Imai K, Kamiya M, Yoshihashi-Nakazato Y, Miyasaka N, et al. Acute Tubulointerstitial nephritis associated with infliximab in a patient with Crohn’s disease. Intern Med. 2016;55(10):1367–70.CrossRef
20.
go back to reference Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–86.CrossRef Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–86.CrossRef
21.
go back to reference Suarez-Fueyo A, Bradley SJ, Klatzmann D, Tsokos GC. T cells and autoimmune kidney disease. Nat Rev Nephrol. 2017;13(6):329–43.CrossRef Suarez-Fueyo A, Bradley SJ, Klatzmann D, Tsokos GC. T cells and autoimmune kidney disease. Nat Rev Nephrol. 2017;13(6):329–43.CrossRef
22.
go back to reference Freedman BI, Spray BJ, Heise ER. HLA associations in IgA nephropathy and focal and segmental glomerulosclerosis. Am J Kidney Dis. 1994;23(3):352–7.CrossRef Freedman BI, Spray BJ, Heise ER. HLA associations in IgA nephropathy and focal and segmental glomerulosclerosis. Am J Kidney Dis. 1994;23(3):352–7.CrossRef
23.
go back to reference Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut. 1999;45(3):395–401.CrossRef Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut. 1999;45(3):395–401.CrossRef
24.
go back to reference Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187–96.CrossRef Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187–96.CrossRef
25.
go back to reference Coppo R. The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition. Pediatr Nephrol. 2018;33(1):53–61.CrossRef Coppo R. The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition. Pediatr Nephrol. 2018;33(1):53–61.CrossRef
26.
go back to reference Coppo R. The pathogenetic potential of environmental antigens in IgA nephropathy. Am J Kidney Dis. 1988;12(5):420–4.CrossRef Coppo R. The pathogenetic potential of environmental antigens in IgA nephropathy. Am J Kidney Dis. 1988;12(5):420–4.CrossRef
27.
go back to reference Smerud HK, Barany P, Lindstrom K, Fernstrom A, Sandell A, Pahlsson P, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant. 2011;26(10):3237–42.CrossRef Smerud HK, Barany P, Lindstrom K, Fernstrom A, Sandell A, Pahlsson P, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant. 2011;26(10):3237–42.CrossRef
28.
go back to reference Wang J, Anders RA, Wu Q, Peng D, Cho JH, Sun Y, et al. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest. 2004;113(6):826–35.CrossRef Wang J, Anders RA, Wu Q, Peng D, Cho JH, Sun Y, et al. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest. 2004;113(6):826–35.CrossRef
29.
go back to reference Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol. 2010;21(10):1783–90.CrossRef Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol. 2010;21(10):1783–90.CrossRef
30.
go back to reference Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther. 2001;15(3):363–9.CrossRef Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther. 2001;15(3):363–9.CrossRef
31.
go back to reference Dehmer C, Greinwald R, Loffler J, Grotz W, Wolf L, Hagmann HB, et al. No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases. Int J Color Dis. 2003;18(5):406–12.CrossRef Dehmer C, Greinwald R, Loffler J, Grotz W, Wolf L, Hagmann HB, et al. No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases. Int J Color Dis. 2003;18(5):406–12.CrossRef
32.
go back to reference Kreisel W, Wolf LM, Grotz W, Grieshaber M. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1996;8(5):461–8.PubMed Kreisel W, Wolf LM, Grotz W, Grieshaber M. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1996;8(5):461–8.PubMed
33.
go back to reference Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther. 2001;15(8):1131–7.CrossRef Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther. 2001;15(8):1131–7.CrossRef
34.
go back to reference Chin G, Luxton G, Harvey JM. Infliximab and nephrotic syndrome. Nephrol Dial Transplant. 2005;20(12):2824–6.CrossRef Chin G, Luxton G, Harvey JM. Infliximab and nephrotic syndrome. Nephrol Dial Transplant. 2005;20(12):2824–6.CrossRef
35.
go back to reference Oikonomou KA, Kapsoritakis AN, Stefanidis I, Potamianos SP. Drug-induced nephrotoxicity in inflammatory bowel disease. Nephron Clin Pract. 2011;119(2):c89–94 discussion c96.CrossRef Oikonomou KA, Kapsoritakis AN, Stefanidis I, Potamianos SP. Drug-induced nephrotoxicity in inflammatory bowel disease. Nephron Clin Pract. 2011;119(2):c89–94 discussion c96.CrossRef
36.
go back to reference Sato T, Kawasaki Y, Ito A, Izumi H, Kawamorita N, Yamashita S, et al. Infliximab-induced tubulointerstitial nephritis with image findings of striated Nephrogram in Crohn’s disease. Tohoku J Exp Med. 2018;245(3):149–52.CrossRef Sato T, Kawasaki Y, Ito A, Izumi H, Kawamorita N, Yamashita S, et al. Infliximab-induced tubulointerstitial nephritis with image findings of striated Nephrogram in Crohn’s disease. Tohoku J Exp Med. 2018;245(3):149–52.CrossRef
Metadata
Title
Different renal manifestations associated with very early onset pediatric inflammatory bowel disease: case report and review of literature
Authors
A. Angeletti
S. Arrigo
A. Madeo
M. Molteni
E. Vietti
L. Arcuri
M. C. Coccia
P. Gandullia
G. M. Ghiggeri
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02358-2

Other articles of this Issue 1/2021

BMC Nephrology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.